| dbo:abstract |
18F-FMISO or fluoromisonidazole is a radiopharmaceutical used for PET imaging of hypoxia. It consists of a 2-nitroimidazole molecule labelled with the positron-emitter fluorine-18. Hypoxia is considered a negative prognostic marker for many solid tumours, and therefore an agent to detect and quantify it is highly desirable. FMISO was one of the first such agents, after initial synthesis in the late 1980s. It remains among the most popular agents for investigation of hypoxia imaging. (en) |
| dbo:casNumber |
104613-87-8 |
| dbo:chemicalFormula |
C6H818FN3O |
| dbo:fdaUniiCode |
8MSY49469G |
| dbo:thumbnail |
wiki-commons:Special:FilePath/18F-Fluoromisonidazole.svg?width=300 |
| dbo:wikiPageExternalLink |
https://www.ncbi.nlm.nih.gov/books/NBK23099/ |
| dbo:wikiPageID |
47065337 (xsd:integer) |
| dbo:wikiPageLength |
12646 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1124698990 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Prognosis_marker dbr:Breast_cancer dbc:PET_radiotracers dbr:Radiopharmaceutical dbr:Contrast_(vision) dbc:Nitroimidazoles dbr:Clinical_trial dbr:Head_and_neck_cancer dbr:Fluorine-18 dbr:Nitro_compound dbr:Nitroimidazole dbr:Quantification_(science) dbr:Reduction_(chemistry) dbr:Hypoxia_(medical) dbr:Chemotherapy dbr:Positron_emission_tomography dbr:Oncology dbr:Radiotherapy dbr:Treatment_planning dbr:Tumour_hypoxia dbr:Solid_tumours dbr:Brain_tumour dbr:Specificity_and_sensitivity dbr:Diffuse dbr:Overall_survival dbr:Oxidised dbr:File:FMISO_hypoxia_accumulation_mechanism.png |
| dbp:casNumber |
104613 (xsd:integer) |
| dbp:chemicalFormula |
C6H818FN3O (en) |
| dbp:chemspiderid |
396524 (xsd:integer) |
| dbp:drugName |
[18F]Fluoromisonidazole (en) |
| dbp:iupacName |
1 (xsd:integer) |
| dbp:molecularWeight |
188.150000 (xsd:double) |
| dbp:stdinchikey |
HIIJZYSUEJYLMX-JZRMKITLSA-N (en) |
| dbp:synonyms |
[18F]FMISO; 1H-1--2-nitroimidazole (en) |
| dbp:unii |
8 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Infobox_drug dbt:Reflist dbt:Cascite dbt:Fdacite |
| dct:subject |
dbc:PET_radiotracers dbc:Nitroimidazoles |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
18F-FMISO or fluoromisonidazole is a radiopharmaceutical used for PET imaging of hypoxia. It consists of a 2-nitroimidazole molecule labelled with the positron-emitter fluorine-18. Hypoxia is considered a negative prognostic marker for many solid tumours, and therefore an agent to detect and quantify it is highly desirable. FMISO was one of the first such agents, after initial synthesis in the late 1980s. It remains among the most popular agents for investigation of hypoxia imaging. (en) |
| rdfs:label |
FMISO (en) |
| owl:sameAs |
wikidata:FMISO https://global.dbpedia.org/id/zN4V |
| prov:wasDerivedFrom |
wikipedia-en:FMISO?oldid=1124698990&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/18F-Fluoromisonidazole.svg wiki-commons:Special:FilePath/FMISO_hypoxia_accumulation_mechanism.png |
| foaf:isPrimaryTopicOf |
wikipedia-en:FMISO |
| foaf:name |
[18F]Fluoromisonidazole (en) |
| is dbo:wikiPageRedirects of |
dbr:C6H8FN3O dbr:18F-MISO dbr:Fluoromisonidazole dbr:F-MISO |
| is dbo:wikiPageWikiLink of |
dbr:Brain_positron_emission_tomography dbr:C6H8FN3O dbr:Tumor_hypoxia dbr:List_of_PET_radiotracers dbr:18F-MISO dbr:Fluoromisonidazole dbr:F-MISO |
| is foaf:primaryTopic of |
wikipedia-en:FMISO |
